EF24 |
カタログ番号GC64496
One-Click Copy Product Info
|
EF24は新型の合成クルクミン類似物である。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 342808-40-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
EF24は新型の合成クルクミン類似物である[1]。EF24は酸化還元に依存するメカニズムを通じて、癌細胞のアポトーシスを誘発する[2]。EF24は抗腫瘍と抗老化の作用を持つ[3-4]。
A549細胞で、EF24 (0μM, 0.5μM, 1μM, 2μM, 4μM, 8μM, 16μM；24時間、48時間)は体外で、NSCLC細胞の成長を阻害する[5]。K562細胞で、EF24 (2μM；24時間)は白血病細胞株で、有力な細胞殺傷活性を示す[6]。SKOV-3で、EF24 (3μM；48時間)は、卵巣癌細胞の増殖と転移を軽減する[7]。
皮下HCC腫瘍マウスモデルで、EF24 (20mg/kg；腹腔内注射；21日間)は腫瘍の成長を阻害し、アポトーシスを誘発する[8]。C57/BL6マウスで、EF24 (200μg/kg；腹腔内注射；14日間)は、赤外線照射後、遠隔肺組織で、JunB、JunCとJunDのレベルの著しい増加を著しく阻害した[9]。DU145皮下腫瘍マウスモデルで、EF24 (200μg/kg；腹腔内注射；4週間)の処理は、腫瘍の成長を著しく遅らせた[10]。
References:
[1]. He Y, Li W, Hu G, et al. Bioactivities of EF24, a novel curcumin analog: a review. Frontiers in Oncology. 2018 Dec 11; 8: 614.
[2]. Adams BK, Cai J, Armstrong J, et al. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anti-cancer drugs. 2005 Mar 1;16(3):263-275.
[3]. Sazdova I, Keremidarska-Markova M, Dimitrova D, et al. Anticarcinogenic potency of EF24: An overview of its pharmacokinetics, efficacy, mechanism of action, and nanoformulation for drug delivery. Cancers. 2023 Nov 20; 15(22): 5478.
[4]. Li W, He Y, Zhang R, et al. The curcumin analog EF24 is a novel senolytic agent. Aging (Albany NY). 2019 Jan 28;11(2):771.
[5]. Chang M, Shang M, Yuan F, et al. EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation. Cancer Cell International. 2021 Dec; 21: 1-3.
[6]. Singh AP, Wax N, Duncan J, et al. Genomic Discovery of EF-24 Targets Unveils Antitumorigenic Mechanisms in Leukemia Cells. bioRxiv. 2024 Oct 16: 2024-2010.
[7]. Zhang D, Wang Y, Dong L, et al. Therapeutic role of EF 24 targeting glucose transporter 1‐mediated metabolism and metastasis in ovarian cancer cells. Cancer science. 2013 Dec; 104(12): 1690-1696.
[8]. Liu H, Liang Y, Wang L, et al. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog. PloS one. 2012 Oct 31; 7(10): e48075.
[9]. Veeraraghavan J, Natarajan M, Awasthi V, et al. EF24, a novel curcumin analogue inhibits oncogenic activation induced by radiation abscopal effect in distant mice lungs. Cancer Research. 2011 Apr 15;71(8_Supplement):4203.
[10]. Yang CH, Yue J, Sims M, et al. The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo. PloS one. 2013 Aug 7; 8(8): e71130.
| 細胞実験[1]: | |
細胞株 | A549細胞 |
準備方法 | 細胞成長/生存率（MTT）アッセイについて、A549細胞を4000細胞で標準96ウェルのプレートに播種し、24時間培養し、接着を確保する。その後、0μM, 0.5μM, 1μM, 2μM, 4μM, 8μMと16μMの最終濃度のEF24を含有する培地で培地を交換した。 |
反応条件 | 0μM, 0.5μM, 1μM, 2μM, 4μM, 8μM, 16μM；24時間、48時間 |
アプリケーション | EF24は体外で、NSCLC細胞の成長を阻害する。 |
| 動物実験 [2]: | |
動物モデル | 皮下HCC腫瘍マウスモデル |
準備方法 | 200µLPBSの中の約2×106 Hepa1-6細胞を各動物の背中に皮下注射した（n=20）。EF24をジメチルスルホキシドに溶解し、塩化ナトリウムに希釈した。注射の10日後、EF24処理のマウス(n = 10)に、用量が20mg/kg/日の200µL EF24を21日間腹腔内（i.p.）注射した。22日目に、腫瘍を摘出し、重さを測った。 |
投与形態 | 20mg/kg；腹腔内注射；21日間 |
アプリケーション | EF24は皮下HCC腫瘍モデルで、腫瘍の成長を阻害し、アポトーシスを誘発する。 |
References: | |
| Cas No. | 342808-40-6 | SDF | |
| Formula | C19H15F2NO | M.Wt | 311.33 |
| 溶解度 | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.212 mL | 16.0601 mL | 32.1203 mL |
| 5 mM | 642.4 μL | 3.212 mL | 6.4241 mL |
| 10 mM | 321.2 μL | 1.606 mL | 3.212 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)